Fully human IgG1 anti-PD-L1 monoclonal antibody under investigation for immunotherapy
Avelumab
Monoclonal antibody
Type
Whole antibody
Source
Human
Target
PD-L1
Clinical data
Trade names
Bavencio
Other names
MSB0010718C
AHFS/Drugs.com
Monograph
MedlinePlus
a617006
License data
US DailyMed: Avelumab
Pregnancy category
AU: D[1]
Routes of administration
Intravenous infusion
ATC code
L01FF04 (WHO)
Legal status
Legal status
AU: S4 (Prescription only)
CA: ℞-only[2][3][4]
US: ℞-only[5]
EU: Rx-only
Pharmacokinetic data
Metabolism
Proteolysis
Elimination half-life
6.1 days
Identifiers
CAS Number
1537032-82-8
DrugBank
DB11945
ChemSpider
none
UNII
KXG2PJ551I
KEGG
D10817Y
Chemical and physical data
Formula
C6374H9898N1694O2010S44
Molar mass
143831.79 g·mol−1
Avelumab, sold under the brand name Bavencio, is a fully human monoclonal antibody medication for the treatment of Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma.[5]
Common side effects include fatigue, musculoskeletal pain, diarrhea, nausea, infusion-related reactions, rash, decreased appetite and swelling of the limbs (peripheral edema).[6]
Avelumab targets the protein programmed death-ligand 1 (PD-L1). It has received orphan drug designation by the European Medicines Agency (EMA) for the treatment of gastric cancer in January 2017.[7] The US Food and Drug Administration (FDA) approved it in March 2017 for Merkel-cell carcinoma.[6] an aggressive type of skin cancer. The EMA approved it in September 2017 for the same indication.[8] This is the first FDA-approved treatment for metastatic MCC, a rare, aggressive form of skin cancer.[6] Avelumab was developed by Merck KGaA and Pfizer.[9]
^"Avelumab (Bavencio) Use During Pregnancy". Drugs.com. 29 May 2019. Retrieved 2 August 2020.
^"Regulatory Decision Summary for Bavencio". 23 October 2014.
^"Cancer therapies". Health Canada. 8 May 2018. Retrieved 13 April 2024.
^"Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada. 14 October 2020. Retrieved 17 April 2024.
^ ab"Bavencio- avelumab injection, solution, concentrate". DailyMed. 2 July 2020. Retrieved 2 August 2020.
^ abcCite error: The named reference FDA PR 20170323 was invoked but never defined (see the help page).
^"Public summary of opinion on orphan designation: Avelumab for the treatment of gastric cancer" (PDF). European Medicines Agency. 9 January 2017.
^"Bavencio: EPAR - Product Information" (PDF). European Medicines Agency. 18 September 2017.
^Merck-Pfizer Alliance. "Merck-Pfizer Alliance Avelumab Fact Sheet" (PDF). Archived from the original (PDF) on 17 May 2017. Retrieved 2 December 2015.
Avelumab, sold under the brand name Bavencio, is a fully human monoclonal antibody medication for the treatment of Merkel cell carcinoma, urothelial carcinoma...
bladder cancer. Anti-PD-L1 antibodies currently in development include avelumab and durvalumab, in addition to an inhibitory affimer. Other modes of enhancing...
collaboration with Pfizer to evaluate combination of Bempegaldesleukin with avelumab and talazoparib or enzalutamide in multiple cancers. In March 2022 it was...
BMS-936559 (Bristol Myers Squibb). Both atezolizumab (MPDL3280A, Roche) and avelumab (Merck KGaA, Darmstadt, Germany and Pfizer) target the similar PD-L1 receptor...
results in more progression of the cancer than pembrolizumab, axitinib and avelumab. In comparison to pembrolizumab and axitinib, it probably results in more...
Dostarlimab exhibits better efficacy than other PD-1 inhibitors, such as avelumab and durvalumab, in dMMR advanced endometrial cancers. Efficacy of the drug...
work has led to the establishment of several novel drugs (cabozantinib, avelumab, pazopanib and others including combinations) and prognostic factors in...
nivolumab, and are inhibitors of programmed cell-death ligand 1 (PD-1). Avelumab, atezolizumab and durvalumab are inhibitors of PD-L1. Pembrolizumab probably...
Palbociclib (CDK4/6 inhibitor), Fulvestrant (estrogen receptor antagonist), and Avelumab (monoclonal antibody) for the treatment of metastatic ER+ HER- breast cancer...
antibody drugs, e.g. pembrolizumab, atezolizumab, durvalumab nivolumab, and avelumab, bind to and inhibit the stimulation of PD-1 on CD8+ T cells by PD-L1....
refractory to PD-L1 or PD-1 therapies such as pembrolizumab, nivolumab, avelumab) Second-line HNSCC In each of the three indications, a first cohort of...
A.; Uemura, Motohide; Pal, Sumanta K.; Alekseev, Boris (2020-09-07). "Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker...
in cancer and genitourinary tumors. She led the bladder cancer study of avelumab that resulted in FDA approval in advanced bladder cancer. Apolo received...
(investigator’s choice). Dr. Sternberg is a PI on the Javelin Bladder 100 trial with avelumab maintenance therapy that has changed clinical practice guidelines worldwide...
Global Information